aflibercept high-dose Eylea HD
Selected indexed studies
- High-Dose Aflibercept for Neovascular AMD and DME in Suboptimal Responders to Standard-Dose Aflibercept. (J Vitreoretin Dis, 2023) [PMID:37006663]
- Resolution of subretinal fluid in intractable central serous chorioretinopathy with high-dose intravitreal aflibercept. (Am J Ophthalmol Case Rep, 2025) [PMID:39917551]
- Long-acting delivery and therapies for neovascular age-related macular degeneration. (Expert Opin Biol Ther, 2024) [PMID:38953649]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- High-Dose Aflibercept for Neovascular AMD and DME in Suboptimal Responders to Standard-Dose Aflibercept. (2023) pubmed
- Resolution of subretinal fluid in intractable central serous chorioretinopathy with high-dose intravitreal aflibercept. (2025) pubmed
- Long-acting delivery and therapies for neovascular age-related macular degeneration. (2024) pubmed
- Double-dose investigation of aflibercept in neovascular age-related macular degeneration (DIANA): a real-world study. (2024) pubmed
- Comparison of Bevacizumab and Aflibercept for Suppression of Angiogenesis in Human Retinal Microvascular Endothelial Cells. (2023) pubmed
- Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial. (2020) pubmed
- Adverse Events Reported with Standard-Dose and High-Dose Aflibercept: A FAERS Pharmacovigilance Study. (2026) pubmed